MX379318B - Metodos para tratar trastornos de sueño de ritmo circadiano. - Google Patents

Metodos para tratar trastornos de sueño de ritmo circadiano.

Info

Publication number
MX379318B
MX379318B MX2018013663A MX2018013663A MX379318B MX 379318 B MX379318 B MX 379318B MX 2018013663 A MX2018013663 A MX 2018013663A MX 2018013663 A MX2018013663 A MX 2018013663A MX 379318 B MX379318 B MX 379318B
Authority
MX
Mexico
Prior art keywords
methods
sleep disorders
circadian rhythm
rhythm sleep
treating circadian
Prior art date
Application number
MX2018013663A
Other languages
English (en)
Spanish (es)
Other versions
MX2018013663A (es
Inventor
Andrew Satlin
Carsten T Beuckmann
Margaret Moline
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of MX2018013663A publication Critical patent/MX2018013663A/es
Publication of MX379318B publication Critical patent/MX379318B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/501Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Dermatology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MX2018013663A 2016-05-12 2017-05-11 Metodos para tratar trastornos de sueño de ritmo circadiano. MX379318B (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201662335599P 2016-05-12 2016-05-12
US201662335611P 2016-05-12 2016-05-12
US201662413976P 2016-10-27 2016-10-27
US201662414606P 2016-10-28 2016-10-28
US201662414599P 2016-10-28 2016-10-28
PCT/US2017/032228 WO2017197160A1 (en) 2016-05-12 2017-05-11 Methods of treating circadian rhythm sleep disorders

Publications (2)

Publication Number Publication Date
MX2018013663A MX2018013663A (es) 2019-07-18
MX379318B true MX379318B (es) 2025-03-10

Family

ID=58745465

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018013663A MX379318B (es) 2016-05-12 2017-05-11 Metodos para tratar trastornos de sueño de ritmo circadiano.

Country Status (16)

Country Link
US (2) US11096941B2 (https=)
EP (2) EP4056180A1 (https=)
JP (2) JP6888026B2 (https=)
KR (2) KR102511855B1 (https=)
CN (1) CN109640998A (https=)
AU (3) AU2017264871B2 (https=)
CA (1) CA3022068A1 (https=)
ES (1) ES2904625T3 (https=)
IL (2) IL291791B2 (https=)
MX (1) MX379318B (https=)
MY (1) MY199382A (https=)
RU (1) RU2763493C2 (https=)
SG (1) SG11201809527UA (https=)
TW (1) TWI795359B (https=)
WO (1) WO2017197160A1 (https=)
ZA (1) ZA201807903B (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11096941B2 (en) * 2016-05-12 2021-08-24 Eisai R&D Management Co.. Ltd. Methods of treating circadian rhythm sleep disorders
BR112021026291A2 (pt) * 2019-06-26 2022-03-03 Eisai R&D Man Co Ltd Lemborexant para tratar problemas de sono
JP2022538170A (ja) * 2019-06-26 2022-08-31 エーザイ・アール・アンド・ディー・マネジメント株式会社 睡眠問題の治療のためのレンボレキサント
WO2020263253A1 (en) * 2019-06-26 2020-12-30 Moline Margaret Lemborexant for treating sleep issues
JP7573015B2 (ja) * 2019-09-13 2024-10-24 エーザイ・アール・アンド・ディー・マネジメント株式会社 不眠症治療用医薬組成物
JP2023506025A (ja) * 2019-12-11 2023-02-14 テバ チェコ インダストリーズ エス.アール.オー. レンボレキサントの固体形態
MX2022008260A (es) * 2020-01-16 2022-08-04 Eisai R&D Man Co Ltd Sustancia farmacologica de lemborexant y composicion medicinal que la comprende.
CN111450076A (zh) * 2020-05-25 2020-07-28 安徽省逸欣铭医药科技有限公司 一种Lemborexant软胶囊组合物及其制备方法
CN114159568B (zh) * 2020-09-11 2025-08-01 北京原基华毅生物科技有限公司 Sik抑制剂在制备用于预防和/或治疗睡眠障碍的药物中的应用
WO2023007320A1 (en) * 2021-07-26 2023-02-02 Eisai R&D Mangement Co., Ltd. Lemborexant for use in methods of treating irregular sleep-wake rhythm disorder and circadian rhythm sleep disorders associated with neurodegenerative diseases
CN116421605B (zh) * 2022-01-04 2024-08-02 中国科学院脑科学与智能技术卓越创新中心 Isx-9在治疗衰老相关的昼夜节律幅度下降和睡眠障碍方面的应用
WO2024064897A1 (en) 2022-09-23 2024-03-28 Eisai R&D Management Co., Ltd. Methods of reducing neurodegeneration associated with neurodegenerative diseases
CN121646412A (zh) 2023-08-08 2026-03-10 株式会社明治 昼夜节律的调整

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA06009377A (es) * 2004-02-20 2007-03-07 Lifescape Biosciences Inc Composiciones y metodos para regulacion del sueno.
ATE458740T1 (de) * 2006-08-28 2010-03-15 Actelion Pharmaceuticals Ltd 1,4,5,6,7,8-hexahydro-1,2,5-triaza-azulen- derivate als orexinrezeptor-antagonisten
AU2011304285B2 (en) 2010-09-22 2015-01-29 Eisai R&D Management Co., Ltd. Cyclopropane compound
CA2863413A1 (en) * 2012-02-07 2013-08-15 Eolas Therapeutics, Inc. Substituted prolines / piperidines as orexin receptor antagonists
ES2843952T3 (es) 2014-10-23 2021-07-21 Eisai R&D Man Co Ltd Composiciones para tratar el insomnio
US11096941B2 (en) * 2016-05-12 2021-08-24 Eisai R&D Management Co.. Ltd. Methods of treating circadian rhythm sleep disorders

Also Published As

Publication number Publication date
RU2018143809A3 (https=) 2020-09-17
KR102511855B1 (ko) 2023-03-20
CA3022068A1 (en) 2017-11-16
BR112018073037A2 (pt) 2019-02-26
JP6888026B2 (ja) 2021-06-16
AU2025205336A1 (en) 2025-07-31
MX2018013663A (es) 2019-07-18
JP2019518732A (ja) 2019-07-04
JP2021120410A (ja) 2021-08-19
RU2018143809A (ru) 2020-06-15
US20200179382A1 (en) 2020-06-11
US11096941B2 (en) 2021-08-24
WO2017197160A1 (en) 2017-11-16
AU2023203418A1 (en) 2023-06-29
RU2763493C2 (ru) 2021-12-29
NZ748555A (en) 2025-06-27
IL291791B2 (en) 2025-09-01
IL262803B (en) 2022-05-01
SG11201809527UA (en) 2018-11-29
KR20190013820A (ko) 2019-02-11
CN109640998A (zh) 2019-04-16
EP3454859A1 (en) 2019-03-20
IL291791A (en) 2022-06-01
ZA201807903B (en) 2021-04-28
AU2017264871B2 (en) 2023-03-16
AU2017264871A1 (en) 2018-11-15
IL291791B1 (en) 2025-05-01
US20210353625A1 (en) 2021-11-18
IL262803A (en) 2018-12-31
KR20230043227A (ko) 2023-03-30
TW201740952A (zh) 2017-12-01
EP4056180A1 (en) 2022-09-14
MY199382A (en) 2023-10-25
TWI795359B (zh) 2023-03-11
JP7150096B2 (ja) 2022-10-07
EP3454859B1 (en) 2021-12-01
ES2904625T3 (es) 2022-04-05

Similar Documents

Publication Publication Date Title
MX379318B (es) Metodos para tratar trastornos de sueño de ritmo circadiano.
PH12019501575A1 (en) ISOFORM-SPECIFIC, CONTEXT-PERMISSIVE TGFá1 INHIBITORS AND USE THEREOF
PH12016501809A1 (en) Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
JO3553B1 (ar) تعديل المناعة ضد الورم
UY35464A (es) Inhibidores covalentes de kras g12c.
EA201790737A1 (ru) Комбинированная терапия
MX2023000796A (es) Composicion farmaceutica, metodos para tratamiento y sus usos.
HUE061761T2 (hu) Tetrahidropiranil-amino-pirrolopirimidinon felhasználásra BTK-által közvetített zavarok kezelésében
BR112018001853A2 (pt) métodos para tratamento de um distúrbio e para melhoria do tratamento de um distúrbio
DK3442513T3 (da) Anvendelse af cannabidiolsyre i behandling af autismespektrumforstyrrelse og forbundne forstyrrelser
BR112017018964A2 (pt) uso de plinabulin e métodos para tratar tumor cerebral
BR112017005598A2 (pt) macrociclos peptidomiméticos e usos dos mesmos
MX385425B (es) Irinotecán liposomal y oxaliplatino, 5-fluoroacilo y leucovorina para usarse en el tratamiento de cáncer pancreático metastásico.
HUE060496T2 (hu) Terápiás vegyületek és készítmények szociális zavarok és szerhasználati zavarok kezelésére
CY1126258T1 (el) Ενωσεις ινδολινονης και χρηση αυτων στη θεραπεια ινωτικων ασθενειων
HUE039858T2 (hu) 2,6-Szubsztituált purinszármazékok és alkalmazásuk proliferatív rendellenességek kezelésében
CO2020001107A2 (es) Moduladores terapéuticos del modo inverso de la atp sintasa
EP3709984C0 (en) COMBINATION OF CANNABIDIOL AND BUPRENORPHINE AND ITS USE FOR THE TREATMENT OF CHRONIC PAIN
CY1125113T1 (el) Συνθεσεις και μεθοδοι για χρηση στην αγωγη της ομοκυστινουριας
BR112016015997A2 (pt) ?composições farmacêuticas que compreendem 15- hepe e métodos para tratar asma e distúrbios pulmonares com o uso das mesmas?
IL253582B (en) Detection and treatment of malignant tumours in the cns
EP3402468C0 (en) PI3K P-DELTA 110 INHIBITORS FOR USE IN DELIVERY OF VIRUSES TO TREAT CANCER
MX2018002298A (es) Metodos de uso de interleucina 10 para el tratamiento de enfermedades y trastornos.
PL3630112T3 (pl) Kombinacja regorafenibu i niwolumabu w leczeniu nowotworu
HUE054910T2 (hu) Indazole vegyületek ín és/vagy ínszalag sérülés kezelésében történõ alkalmazásra